---
title: "Bank of China Remains a Buy on 3SBio (TRSBF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281468789.md"
description: "In a report released yesterday, from Bank of China maintained a Buy rating on 3SBio, with a price target of HK$38.30.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released yesterday, CMB International Securities also maintained a Buy rating on the stock with a HK$34.87 price target."
datetime: "2026-04-02T05:18:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281468789.md)
  - [en](https://longbridge.com/en/news/281468789.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281468789.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281468789.md) | [繁體中文](https://longbridge.com/zh-HK/news/281468789.md)


# Bank of China Remains a Buy on 3SBio (TRSBF)

In a report released yesterday, from Bank of China maintained a Buy rating on 3SBio, with a price target of HK$38.30.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

In a report released yesterday, CMB International Securities also maintained a Buy rating on the stock with a HK$34.87 price target.

### Related Stocks

- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md)
- [3SBIO (01530.HK)](https://longbridge.com/en/quote/01530.HK.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

- [Simcere Pharmaceutical Group Limited (2096) Receives a Buy from Bank of China](https://longbridge.com/en/news/281137424.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/en/news/281054154.md)
- [Zhongtai Securities Sticks to Its Buy Rating for Wasion Holdings Limited (3393)](https://longbridge.com/en/news/281141455.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [3SBio Proposes Spinoff, Hong Kong Listing of Unit Mandi](https://longbridge.com/en/news/266844070.md)